|
1
|
Lind L: Circulating markers of
inflammation and atherosclerosis. Atherosclerosis. 169:203–214.
2003.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Noels H and Weber C: Editorial comment:
Catching up with important players in atherosclerosis: Type 1
interferons and neutrophils. Curr Opin Lipidol. 22:144–145.
2011.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Weber C and Noels H: Atherosclerosis:
Current pathogenesis and therapeutic options. Nat Med.
17:1410–1422. 2011.PubMed/NCBI View
Article : Google Scholar
|
|
4
|
Heinecke JW: Oxidants and antioxidants in
the pathogenesis of atherosclerosis: Implications for the oxidized
low density lipoprotein hypothesis. Atherosclerosis. 141:1–15.
1998.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Steinberg D, Parthasarathy S, Carew TE,
Khoo JC and Witztum JL: Beyond cholesterol. Modifications of
low-density lipoprotein that increase its atherogenicity. N Engl J
Med. 320:915–924. 1989.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Yoshida H and Kisugi R: Mechanisms of LDL
oxidation. Clin Chim Acta. 411:1875–1882. 2010.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Chen K, Thomas SR and Keaney JF Jr: Beyond
LDL oxidation: ROS in vascular signal transduction. Free Radic Biol
Med. 35:117–132. 2003.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Obama T, Kato R, Masuda Y, Takahashi K,
Aiuchi T and Itabe H: Analysis of modified apolipoprotein B-100
structures formed in oxidized low-density lipoprotein using
LC-MS/MS. Proteomics. 7:2132–2141. 2007.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Sparrow CP, Parthasarathy S and Steinberg
D: Enzymatic modification of low density lipoprotein by purified
lipoxygenase plus phospholipase A2 mimics cell-mediated oxidative
modification. J Lipid Res. 29:745–753. 1988.PubMed/NCBI
|
|
10
|
Malle E, Waeg G, Schreiber R, Gröne EF,
Sattler W and Gröne HJ: Immunohistochemical evidence for the
myeloperoxidase/H2O2/halide system in human atherosclerotic
lesions: Colocalization of myeloperoxidase and hypoch. Eur J
Biochem. 267:4495–4503. 2000.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Hazell LJ, Arnold L, Flowers D, Waeg G,
Malle E and Stocker R: Presence of hypochlorite-modified proteins
in human atherosclerotic lesions. J Clin Invest. 97:1535–1544.
1996.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Hansson GK: Regulation of immune
mechanisms in atherosclerosis. Ann N Y Acad Sci. 947:157–166.
2001.PubMed/NCBI
|
|
13
|
Vanhamme L, Zouaoui Boudjeltia K, Van
Antwerpen P and Delporte C: The other myeloperoxidase: Emerging
functions. Arch Biochem Biophys. 649:1–14. 2018.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Brennan ML, Penn MS, Van Lente F, Nambi V,
Shishehbor MH, Aviles RJ, Goormastic M, Pepoy ML, McErlean ES,
Topol EJ, et al: Prognostic value of myeloperoxidase in patients
with chest pain. N Engl J Med. 349:1595–1604. 2003.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Baldus S, Heeschen C, Meinertz T, Zeiher
AM, Eiserich JP, Munzel T, Simmons ML and Hamm CW: CAPTURE
Investigators: Myeloperoxidase serum levels predict risk in
patients with acute coronary syndromes. Circulation. 108:1440–1445.
2003.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Delporte C, Van Antwerpen P, Vanhamme L,
Roumeguère T and Zouaoui Boudjeltia K: Low-density lipoprotein
modified by myeloperoxidase in inflammatory pathways and clinical
studies. Mediators Inflamm. 2013(971579)2013.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Kruth HS, Huang W, Ishii I and Zhang WY:
Macrophage foam cell formation with native low density lipoprotein.
J Biol Chem. 277:34573–34580. 2002.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Vicca S, Hennequin C, Nguyen-Khoa T, Massy
ZA, Descamps-Latscha B, Drüeke TB and Lacour B: Caspase-dependent
apoptosis in THP-1 cells exposed to oxidized low-density
lipoproteins. Biochem Biophys Res Commun. 273:948–954.
2000.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Daher J, Martin M, Rousseau A, Nuyens V,
Fayyad-Kazan H, Van Antwerpen P, Courbebaisse G, Martiat P, Badran
B, Dequiedt F, et al: Myeloperoxidase oxidized LDL interferes with
endothelial cell motility through miR-22 and heme oxygenase 1
induction: Possible involvement in reendothelialization of vascular
injuries. Mediators Inflamm. 2014(134635)2014.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Chellan B, Rojas E, Zhang C and Hofmann
Bowman MA: Enzyme-modified non-oxidized LDL (ELDL) induces human
coronary artery smooth muscle cell transformation to a migratory
and osteoblast-like phenotype. Sci Rep. 8(11954)2018.PubMed/NCBI View Article : Google Scholar
|
|
21
|
El Samad G, Bazzi S, Karam M, Boudjeltia
KZ, Vanhamme L and Daher J: Effect of myeloperoxidase modified LDL
on bovine and human aortic endothelial cells. Exp Ther Med.
18:4567–4574. 2019.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Zouaoui Boudjeltia K, Daher J, Van
Antwerpen P, Moguilevsky N, Delree P, Ducobu J, Raes M, Badran B,
Vanhaeverbeek M, Brohee D, et al: Exposure of endothelial cells to
physiological levels of myeloperoxidase-modified LDL delays
pericellular fibrinolysis. PLoS One. 7(e38810)2012.PubMed/NCBI View Article : Google Scholar
|
